about
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerFAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeuticsFocal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular CarcinomaDPP in the matrix mediates cell adhesion but is not restricted to stickiness: a tale of signaling.Podocyte p53 Limits the Severity of Experimental Alport Syndrome.Supervillin-mediated suppression of p53 protein enhances cell survival.Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.Erythroid cells generated in the absence of specific β1-integrin heterodimers accumulate reactive oxygen species at homeostasis and are unable to mount effective antioxidant defenses.FAK and Nanog cross talk with p53 in cancer stem cells.Role of ion transport in control of apoptotic cell death.NANOG: a promising target for digestive malignant tumorsThe extracellular matrix modulates the hallmarks of cancer.Inside the Cell: Integrins as New Governors of Nuclear Alterations?The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.The physical interaction of p53 and plakoglobin is necessary for their synergistic inhibition of migration and invasion.Integrins and p53 pathways in glioblastoma resistance to temozolomide.Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations.Integrin and FAK Regulation of Human Pluripotent Stem Cells.Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
P2860
Q26774789-6F9488B7-0CC2-421D-83F3-64721CBB8510Q34365958-952F6F1C-4851-48CC-8A4A-D08183EB4FBDQ36244298-E7D5ED4D-146B-432D-852D-4934F78F7BBDQ36338664-A519E47E-82DF-46DE-B8F1-D72601162041Q36417903-5BFA524F-E030-428F-BBFF-B1F3604C3A5AQ36685259-B77062AB-D49F-4BD7-A9C0-1C6798E57111Q37209539-5790A7F6-6720-460B-8F93-547A14DD0D51Q37273203-7B81CAF6-9968-4C9A-A2F4-5C064B55DF06Q38039165-A439B2D0-2087-4806-94A3-6CC92CAEB876Q38110755-3211ED79-CDB2-43AB-A86E-2D8C9935F00FQ38256341-AD806532-7749-4444-A156-3CA6BDFD5614Q38266276-892A9318-B1F8-4DAC-94AC-EF83CBB1F95DQ38690278-94593402-F88B-4BAB-9D51-FB36134D6C15Q39198605-4FD331C7-4BC8-45F9-8D0A-3A7099F37BD5Q41225724-A1F11A42-F01C-4208-AB05-486901107A61Q41630032-556126A0-E0A1-474B-BEAA-CD80E1B87540Q45841984-F65C28CE-C76F-48D3-91AF-97A7F9AE984EQ47140528-3BAB7E66-8947-4DE2-B1DE-29BAD24B942FQ48363650-4739DF8E-299D-4D1A-8CE8-D697AC23DEFE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FAK and p53 protein interactions.
@en
FAK and p53 protein interactions.
@nl
type
label
FAK and p53 protein interactions.
@en
FAK and p53 protein interactions.
@nl
prefLabel
FAK and p53 protein interactions.
@en
FAK and p53 protein interactions.
@nl
P2860
P1476
FAK and p53 protein interactions.
@en
P2093
Vita M Golubovskaya
William G Cance
P2860
P304
P356
10.2174/187152011796817619
P577
2011-09-01T00:00:00Z